Forefront Analytics, LLC
13F holdings for Q2 2026 · WEST CONSHOHOCKEN, PA · filed August 13, 2026
Forefront Analytics, LLC reported $92.0M in 13F securities across 37 holdings for Q2 2026, in a Form 13F filed August 13, 2026. The largest positions were Vanguard Ftse Emerging Markets ETF (11.7%), ESGD (11.6%), ESGE (11.4%). Reported value fell 16.3% from the quarter before. It opened 0 new positions, added to 18, trimmed 15 and sold out of 2.
- 13F value Q2 2026
- $92.0M
- Holdings
- 37
- Change vs prior quarter
- -16.3%
- Rank by 13F value
- #8,348
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| Vanguard Ftse Emerging Markets ETF | $10.8M | 11.7% | 180,376 | +0.1% | Added |
| ESGD iShares ESG Aware MSCI EAFE ETF | $10.7M | 11.6% | 104,247 | -59.0% | Trimmed |
| ESGE iShares ESG Aware MSCI EM ETF | $10.5M | 11.4% | 192,398 | -47.9% | Trimmed |
| iShares TR | $9.4M | 10.2% | 342,756 | +403.4% | Added |
| iShares TR | $8.4M | 9.1% | 24,434 | +0.8% | Added |
| Nushares ETF TR | $7.0M | 7.7% | 140,912 | -28.0% | Trimmed |
| DBX ETF TR | $6.9M | 7.5% | 126,734 | -0.1% | Trimmed |
| Flexshares TR | $5.1M | 5.5% | 21,669 | -51.0% | Trimmed |
| NVDA NVIDIA Corporation | $3.9M | 4.2% | 19,532 | +37.2% | Added |
| Vanguard Ftse Developed Markets ETF | $3.4M | 3.7% | 47,559 | +0.5% | Added |
| iShares TR | $3.3M | 3.6% | 4,450 | -0.5% | Trimmed |
| iShares Inc | $2.6M | 2.8% | 58,203 | -0.6% | Trimmed |
| JPM JP Morgan Chase & Co. | $1.6M | 1.8% | 4,997 | +0.3% | Added |
| DE Deere & Company | $743K | 0.8% | 1,172 | +3.2% | Added |
| UNH UnitedHealth Group Incorporated | $586K | 0.6% | 1,409 | -28.9% | Trimmed |
| INCY Incyte Corp. | $577K | 0.6% | 5,091 | +20.3% | Added |
| EW Edwards Lifesciences Corporation | $557K | 0.6% | 6,158 | -6.3% | Trimmed |
| Proshares TR | $551K | 0.6% | 8,180 | +0.2% | Added |
| Proshares TR | $538K | 0.6% | 7,997 | 0% | Unchanged |
| ABT Abbott Laboratories | $514K | 0.6% | 5,665 | +12.3% | Added |
| Wisdomtree TR | $476K | 0.5% | 7,020 | -14.7% | Trimmed |
| PFE Pfizer Inc. | $438K | 0.5% | 18,210 | +39.1% | Added |
| Medtronic PLC SHS | $416K | 0.5% | 5,319 | 0% | Unchanged |
| DHR Danaher Corporation | $389K | 0.4% | 2,040 | +58.4% | Added |
| TMO Thermo Fisher Scientific Inc | $336K | 0.4% | 669 | +15.5% | Added |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $92.0M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- iShares TR Added+$7.5M
- NVDA NVIDIA Corporation Added+$1.1M
- DHR Danaher Corporation Added+$143K
- PFE Pfizer Inc. Added+$123K
- INCY Incyte Corp. Added+$97K
- Zura Bio LTD Added+$71K
- iShares TR Added+$69K
- ABT Abbott Laboratories Added+$56K
- CTMX CytomX Therapeutics Inc. Added+$47K
- TMO Thermo Fisher Scientific Inc Added+$45K
Biggest sells in Q2 2026
- ESGD iShares ESG Aware MSCI EAFE ETF Trimmed-$15.4M
- ESGE iShares ESG Aware MSCI EM ETF Trimmed-$9.7M
- Flexshares TR Trimmed-$5.3M
- Nushares ETF TR Trimmed-$2.7M
- UNH UnitedHealth Group Incorporated Trimmed-$239K
- Schwab Strategic TR Trimmed-$236K
- Dimensional ETF Trust Sold out-$222K
- LEGN Legend Biotech Corporation Trimmed-$147K
- Wisdomtree TR Trimmed-$82K
- Vanguard Morningstar Value ETF Trimmed-$51K
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 0 new, 18 added, 15 trimmed, 2 sold out.
Sector mix
- Not listed with us64.7%
- n/a23.1%
- Health Care4.3%
- Technology4.2%
- Finance1.8%
- Industrials1.6%
- Funds and other0.3%
13F value by quarter
More holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| OTF Blue Owl Technology Finance Corp. | $307K | 0.3% | 29,654 | 0% | Unchanged |
| LEGN Legend Biotech Corporation | $305K | 0.3% | 10,568 | -32.5% | Trimmed |
| PM Philip Morris International Inc | $265K | 0.3% | 1,463 | +0.9% | Added |
| REGN Regeneron Pharmaceuticals Inc. | $259K | 0.3% | 415 | -9.8% | Trimmed |
| Schwab Strategic TR | $243K | 0.3% | 7,676 | -49.2% | Trimmed |
| Vanguard Morningstar Value ETF | $236K | 0.3% | 1,084 | -17.7% | Trimmed |
| Zura Bio LTD | $159K | 0.2% | 26,968 | +81.0% | Added |
| GERN Geron Corporation | $114K | 0.1% | 88,779 | +61.1% | Added |
| CTMX CytomX Therapeutics Inc. | $94K | 0.1% | 25,033 | +100.6% | Added |
| BCYC Bicycle Therapeutics plc | $93K | 0.1% | 21,822 | +51.6% | Added |
| NKTX Nkarta Inc. | $82K | 0.1% | 28,955 | -33.9% | Trimmed |
| ANNX Annexon Inc. | $81K | 0.1% | 14,240 | 0% | Unchanged |
Questions about Forefront Analytics, LLC
- What does Forefront Analytics, LLC own?
- In its Form 13F for Q2 2026, Forefront Analytics, LLC reported 37 holdings worth $92.0M. The five largest were Vanguard Ftse Emerging Markets ETF, ESGD, ESGE, iShares TR, iShares TR.
- What did Forefront Analytics, LLC buy and sell in Q2 2026?
- Forefront Analytics, LLC opened 0 new positions, added to 18, trimmed 15 and sold out of 2 compared with the quarter before.
- When did Forefront Analytics, LLC file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 13, 2026.
From Form 13F filed by Forefront Analytics, LLC (SEC CIK 0001696802) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds